Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Revenue (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Revenue for 14 consecutive years, with $15.2 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 6.51% to $15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.6 million through Dec 2025, up 2.0% year-over-year, with the annual reading at $66.4 million for FY2025, 1.84% up from the prior year.
  • Revenue for Q4 2025 was $15.2 million at Aytu Biopharma, up from $13.9 million in the prior quarter.
  • The five-year high for Revenue was $30.7 million in Q2 2023, with the low at $13.9 million in Q3 2025.
  • Average Revenue over 5 years is $20.4 million, with a median of $18.7 million recorded in 2023.
  • The sharpest move saw Revenue soared 61.96% in 2021, then tumbled 52.52% in 2024.
  • Over 5 years, Revenue stood at $23.1 million in 2021, then rose by 13.64% to $26.3 million in 2022, then fell by 28.66% to $18.7 million in 2023, then dropped by 13.48% to $16.2 million in 2024, then dropped by 6.51% to $15.2 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $15.2 million, $13.9 million, and $15.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.